Related Experiment Video

Updated: Jul 5, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Bevacizumab for the treatment of advanced non-small-cell lung cancer

Christian Manegold1

  • 1Heidelberg University Medical Center, Department of Surgery - Interdisciplinary Thoracic Oncology, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany. prof.manegold@t-online.de

Expert Review of Anticancer Therapy
|May 13, 2008
PubMed

Insights

Bevacizumab (Avastin) is a novel therapy targeting VEGF, significantly improving survival for advanced non-small-cell lung cancer (NSCLC) patients. This targeted treatment offers a breakthrough in NSCLC care, delaying disease progression with an acceptable safety profile.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Advances in non-small-cell lung cancer (NSCLC) treatment have been limited, with chemotherapy offering minimal survival benefits.
  • Improved understanding of tumor biology has led to the development of targeted therapies.
  • Angiogenesis, crucial for tumor growth, is a key target for novel treatments.

Purpose of the Study:

  • To evaluate the efficacy and safety of bevacizumab (Avastin) in advanced non-small-cell lung cancer (NSCLC).
  • To assess bevacizumab's impact on disease progression and overall survival compared to traditional chemotherapy.

Main Methods:

  • Bevacizumab targets Vascular Endothelial Growth Factor (VEGF), a critical factor in tumor growth and progression.
  • Bevacizumab-based therapy was administered until disease progression.
  • Patient outcomes, including survival and safety profiles, were monitored.

Main Results:

  • Bevacizumab-based therapy significantly delays disease progression in advanced NSCLC patients.
  • It was the first treatment to improve overall survival beyond one year for advanced NSCLC.
  • The therapy demonstrated a well-characterized and acceptable safety profile in eligible patients.

Conclusions:

  • Bevacizumab represents a significant breakthrough in advanced NSCLC care.
  • It is approved for first-line treatment of NSCLC in the USA and Europe.
  • Ongoing trials aim to expand patient eligibility and further define bevacizumab's role in NSCLC treatment.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring08:45

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Published on: November 13, 2012

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.